Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Sera | - |
dc.contributor.author | Kim, Yesol | - |
dc.contributor.author | Lee, Soo-Been | - |
dc.contributor.author | Kang, Hyeok-Gu | - |
dc.contributor.author | Kim, Da-Hyun | - |
dc.contributor.author | Park, Jee Won | - |
dc.contributor.author | Chung, Daeun | - |
dc.contributor.author | Kong, Hyunkyung | - |
dc.contributor.author | Yoo, Kyung Hyun | - |
dc.contributor.author | Kim, Yonghwan | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Chun, Kyung-Hee | - |
dc.contributor.author | Park, Jong Hoon | - |
dc.date.available | 2021-02-22T05:21:27Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 2157-9024 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/1087 | - |
dc.description.abstract | Checkpoint kinase 1 (Chk1) expression is enhanced in most cancers owing to oncogenic activation and constant replicative stress. Chk1 inactivation is a promising cancer therapy, as its inactivation leads to genomic instability, chromosomal catastrophe, and cancer cell death. Herein, we observed that miR-320c, downregulated in triple-negative breast cancer (TNBC) patients, can target Chk1. In addition, downregulated miR-320c expression was associated with poor overall survival in TNBC patients. As Chk1 was associated with the DNA damage response (DDR), we investigated the effect of miR-320c on DDR in TNBC cells. To induce DNA damage, we used platinum-based drugs, especially oxaliplatin, which is most effective with miR-320c. We observed that overexpression of miR-320c in TNBC regulated the oxaliplatin responsiveness by mediating DNA damage repair through the negative regulation of Chk1 in vitro. Furthermore, using a xenograft model, a combination of miR-320c mimic and oxaliplatin effectively inhibited tumor progression. These investigations indicate the potential of miR-320c as a marker of oxaliplatin responsiveness and a therapeutic target to increase the efficacy of chemotherapy in TNBC. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGERNATURE | - |
dc.title | Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancer | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1038/s41389-020-00275-x | - |
dc.identifier.scopusid | 2-s2.0-85092271613 | - |
dc.identifier.wosid | 000579262800001 | - |
dc.identifier.bibliographicCitation | ONCOGENESIS, v.9, no.10, pp 1 - 14 | - |
dc.citation.title | ONCOGENESIS | - |
dc.citation.volume | 9 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 14 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | GEMCITABINE | - |
dc.subject.keywordPlus | BIOGENESIS | - |
dc.subject.keywordPlus | PREDICTION | - |
dc.subject.keywordPlus | PATTERNS | - |
dc.subject.keywordPlus | GENOMICS | - |
dc.subject.keywordPlus | TARGETS | - |
dc.identifier.url | https://www.nature.com/articles/s41389-020-00275-x | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.